Please try another search
For the fiscal year ended 31 December 2016, Calmare Therapeutics Inc revenues increased 24% to $1.1M. Net loss increased 4% to $3.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Interest expense increase of 47% to $1.4M (expense), Personnel and consulting expenses increase of 24% to $2.1M (expense), Other income decrease of 32% to $47K (income).
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Total Revenue | 0.39 | 0.47 | 0.2 | 0.06 |
Gross Profit | 0.27 | 0.34 | 0.15 | 0.03 |
Operating Income | -1.19 | -0.65 | -1.11 | -0.88 |
Net Income | -1.19 | -0.65 | -1.11 | -0.88 |
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Total Assets | 3.88 | 3.99 | 4.12 | 4.29 |
Total Liabilities | 17.7 | 16.65 | 16.14 | 15.43 |
Total Equity | -13.81 | -12.66 | -12.01 | -11.14 |
Period Ending: | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -1.24 | -1.24 | -1.19 | -0.52 |
Cash From Investing Activities | 0 | 0 | ||
Cash From Financing Activities | 1.2 | 1.2 | 1.2 | 0.6 |
Net Change in Cash | -0.04 | -0.04 | 0.01 | 0.08 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review